MTAP deficiency is a novel biomarker in neuroendocrine neoplasms of the lung
Magdalena M. Brune, Luca Roma, Nikolaus Deigendesch, Felix Meissner, Sarp Uzun, Juergen Hench, Obinna Chijioke, Ivana Bratić Hench, Jumpei Kashima, Petra Hirschmann, Julian Pollinger, Keith M. Kerr, David König, Chantal Pauli, Sebastian R. Ott, , Lukas Bubendorf
The paper identifies MTAP deficiency as a biomarker in lung neuroendocrine neoplasms, distinguishing carcinoids from SCLC and LCNEC, and shows it is not caused by 9p21 deletion or promoter hypermethylation.
bioRxiv · Jun 5, 2026 · PreprintPathology